120 patients with metastatic uveal melanoma....Kaplan-Meier estimates of progression-free survival in all evaluable patients (n=96; Panel A) and in patients with tumor harboring mutations in exon 5 of GNAQ or GNA11 (n=80; Panel B) treated as of as of April 22, 2013 are shown. The vertical lines indicate that patients’ data were censored. The median progression-free survival was 7 weeks (95% confidence interval (CI), 4.3–8.4) and 15.9 weeks (95% CI, 8.4–21.1) for all evaluable patients randomized to chemotherapy (n=49) and selumetinib (n=47), respectively.